RR-11a

RR-11a is a synthetic enzyme inhibitor of Legumain (IC50=31-55 nM) . RR-11a can be used for the research of cancer and acute myocardial infarction (AMI) [1][2][3].

Product Specifications

CAS Number

[1361390-56-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Legumain

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/RR-11a.html

Concentration

10mM

Purity

98.08

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](C)C(N[C@@H](C)C(NN(CC(N)=O)C(/C=C/C(ON1C(CCC1=O)=O)=O)=O)=O)=O)OCC2=CC=CC=C2

Molecular Formula

C24H28N6O10

Molecular Weight

560.51

Precautions

H302, H315, H319, H335

References & Citations

[1]Liao D, et al. Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomedicine. 2011 Dec;7 (6) :665-73.|[2]Ralph A, et al. Nanoparticle-based tumor-targeted drug delivery. Patent: CA2809617C|[3]Yang H, et al. Legumain is a predictor of all-cause mortality and potential therapeutic target in acute myocardial infarction. Cell Death Dis. 2020;11 (11) :1014. Published 2020 Nov 26.